Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Study results of NanoViricides anti-dengue drug candidates presented at NIH/NIAID sponsored conference

NanoViricides, Inc.announced today that Anil R. Diwan, PhD, President of the Company, gave a presentation on Friday, February 18th, that discussed the Company's anti-viral technology and more specifically, results from both in-vitro and in-vivo studies of its drug candidates against dengue virus infections that can potentially cause a fatal manifestation, viz. dengue hemorrhagic fever.

23 Feb 2011

Intercell places EUR 33.0m of Senior Unsecured Convertible Notes in private placement transaction

Intercell AG today announced that it successfully placed EUR 33.0m of Senior Unsecured Convertible Notes in a private placement transaction, which was increased due to investor demand.

23 Feb 2011

Biochemist receives STAC grant to find treatment for C. albicans infection in premature infants

A $200,000 grant from the Rhode Island Science and Technology Advisory Council is helping a Bryant University biochemist find a treatment for a fungal infection that is often lethal to premature infants.

23 Feb 2011

New nanoparticle can help develop vaccines against HIV, malaria

MIT engineers have designed a new type of nanoparticle that could safely and effectively deliver vaccines for diseases such as HIV and malaria.

23 Feb 2011

Study: Antibody-directed chemotherapy may be effective for majority of younger AML sufferers

Antibody-directed chemotherapy offers improved survival to particular sub-groups of leukaemia sufferers, a Cardiff University-led study has found.

23 Feb 2011

Why are Chlamydia and HPV major public health problems?

Chlamydia trachomatis is a bacterium that is one of the most common sexually transmitted infections in Europe. Rates in sexually active young people are commonly between 5% and 10%. The number of diagnosed cases is increasing in many European countries, in part due to increased testing and the use of more sensitive tests.

22 Feb 2011

FDA approves OraSure's rapid antibody test to detect HCV

OraSure Technologies, Inc. announced today that its OraQuick HCV Rapid Antibody Test has now been approved by the U.S. Food and Drug Administration for use in detecting HCV antibodies with a fingerstick whole blood sample.

22 Feb 2011

Pharming, Santarus begin RHUCIN Phase IIIb study in patients with Hereditary Angioedema

Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that Pharming has begun an international, multicenter, randomized, placebo-controlled Phase IIIb clinical study evaluating the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema.

22 Feb 2011

MorphoSys completes technology transfer in strategic antibody alliance

MorphoSys AG (FSE: MOR; Prime Standard Segment) announced today that it has received a technology milestone payment from Novartis in connection with completion of the installation of its HuCAL antibody platform at Novartis Institutes for BioMedical Research in Basel, Switzerland.

22 Feb 2011

Life Technologies announces winners of European Ion Torrent PGM Sequencer Grants Program

Life Technologies Corporation, today announced Dr. Angel Carracedo and Dr. Mark Pallen as the winners of the European Ion Torrent Personal Genome Machine (PGM™) Sequencer Grants Program.

19 Feb 2011

Biocare, HJF sign license agreement to distribute antibody against prostate cancer

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has signed a licensing agreement with Biocare Medical, a biotechnology company based in Concord, Calif., for the exclusive worldwide sales and distribution rights for the immunohistochemistry of an antibody designed to detect tumor prevalence in prostate cancer patients.

18 Feb 2011

USPTO issues two patents to VIRxSYS SMaRT RNA platform technology

VIRxSYS Corporation, a privately-held biotechnology company with proprietary RNA payload and lentiviral vector delivery platform technologies, today announced that the United States Patent and Trademark Office has issued the Company two patents for its SMaRT RNA platform technology, capable of reprogramming or repairing genes to create, increase or change protein expression.

18 Feb 2011

World's first cancer stem cell-targeting chemical missile

Deakin University medical scientists have created the world's first cancer stem cell-targeting chemical missile, placing them a step closer to creating a medical 'smart bomb' that would seek out and eradicate the root of cancer cells.

18 Feb 2011

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

Progenics Pharmaceuticals, Inc. today reported positive preliminary data from an ongoing phase 1 study of PSMA ADC, an antibody-drug conjugate designed to selectively deliver chemotherapy to cells that express prostate-specific membrane antigen.

17 Feb 2011

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2010.

17 Feb 2011

MedImmune, PDL BioPharma enter definitive agreement to resolve legal patent disputes

PDL BioPharma, Inc. today announced that PDL and MedImmune, LLC have entered into a definitive settlement agreement that resolves all legal disputes between them, including those relating to MedImmune's product Synagis and PDL's patents known as the Queen et al. patents.

17 Feb 2011

Astellas, AVEO enter development, commercialization agreement for tivozanib

Astellas Pharma Inc., a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.

17 Feb 2011

New fully human monoclonal antibodies to battle Chikungunya

The Singapore Immunology Network (SIgN), an institute of the Agency of Science, Technology and Research (A*STAR), and VIVALIS, a French biopharmaceutical company, announced today the discovery of two new fully human monoclonal antibodies which could battle Chikungunya, a disease that currently has no available vaccine or specific treatment.

16 Feb 2011

Vical announces issuance of U.S. Patent for cytomegalovirus vaccines

Vical Incorporated announced today the issuance of U.S. Patent No. 7,888,112 covering DNA vaccines for cytomegalovirus containing specific gene sequences and formulated with Vical's Vaxfectin adjuvant.

16 Feb 2011

Patient on artificial heart receives heart and kidney transplant

Charles Okeke, the Phoenix husband and father of three, made headlines in May 2010 when he became the first patient in the U.S. to be discharged from a hospital with an artificial heart. With the latest technology, the "Freedom Driver," the man without a heart was able to resume his family life and to be free of the confines of a hospital room.

16 Feb 2011

Antibody News and Research

Further Reading

Study results of NanoViricides anti-dengue drug candidates presented at NIH/NIAID sponsored conference

Intercell places EUR 33.0m of Senior Unsecured Convertible Notes in private placement transaction

Biochemist receives STAC grant to find treatment for C. albicans infection in premature infants

New nanoparticle can help develop vaccines against HIV, malaria

Study: Antibody-directed chemotherapy may be effective for majority of younger AML sufferers

Why are Chlamydia and HPV major public health problems?

FDA approves OraSure's rapid antibody test to detect HCV

Pharming, Santarus begin RHUCIN Phase IIIb study in patients with Hereditary Angioedema

MorphoSys completes technology transfer in strategic antibody alliance

Life Technologies announces winners of European Ion Torrent PGM Sequencer Grants Program

Biocare, HJF sign license agreement to distribute antibody against prostate cancer

USPTO issues two patents to VIRxSYS SMaRT RNA platform technology

World's first cancer stem cell-targeting chemical missile

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

MedImmune, PDL BioPharma enter definitive agreement to resolve legal patent disputes

Astellas, AVEO enter development, commercialization agreement for tivozanib

New fully human monoclonal antibodies to battle Chikungunya

Vical announces issuance of U.S. Patent for cytomegalovirus vaccines

Patient on artificial heart receives heart and kidney transplant

Immunology eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News